Cancer Research Versailles No Abst Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4035-4041, August 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishioka, Y.
Right arrow Articles by Tahara, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishioka, Y.
Right arrow Articles by Tahara, H.
[Cancer Research 59, 4035-4041, August 15, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 121

Yasuhiko Nishioka, Motohiro Hirao, Paul D. Robbins, Michael T. Lotze and Hideaki Tahara2

Departments of Surgery [Y. N., M. H., M. T. L., H. T.] and Molecular Genetics and Biochemistry [Y. N., M. H., P. D. R., M. T. L., H. T.], School of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213

Bone marrow-derived dendritic cells (BM-DCs) retrovirally transduced with genes encoding murine interleukin (IL)-12 stably expressed bioactive IL-12 protein at high levels. Intratumoral injection with IL-12 gene-modified BM-DCs resulted in regression of day 7 established weakly immunogenic tumors (MCA205, B16, and D122). This antitumor effect was substantially better than that of IL-12-transduced syngeneic fibroblasts or nontransduced BM-DCs. Furthermore, intratumoral injection with IL-12-transduced dendritic cells (DCs) induced specific TH1-type responses to the tumor in regional lymph nodes and spleen at levels greater than those of IL-12-transduced fibroblasts or nontransduced BM-DCs. Trafficking studies confirmed that intratumorally injected IL-12-transduced DCs, but not fibroblasts, could migrate to the draining lymph node to the same extent as nontransduced BM-DCs. This strategy designed to deliver genetically modified DCs to tumor sites is associated with systemic and therapeutic antitumor immunity and is an alternative approach to those that use delivery of DCs loaded with tumor antigen. These results support the clinical application of IL-12 gene-modified DCs in patients with cancer.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. Gustafsson, M. Ingelsten, L. Bergqvist, J. Nystrom, B. Andersson, and A. Karlsson-Parra
Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
Cancer Res., July 15, 2008; 68(14): 5965 - 5971.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Darmanin, J. Chen, S. Zhao, H. Cui, R. Shirkoohi, N. Kubo, Y. Kuge, N. Tamaki, K. Nakagawa, J.-i. Hamada, et al.
All-trans Retinoic Acid Enhances Murine Dendritic Cell Migration to Draining Lymph Nodes via the Balance of Matrix Metalloproteinases and Their Inhibitors
J. Immunol., October 1, 2007; 179(7): 4616 - 4625.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Mukhopadhaya, J. Mendecki, X. Dong, L. Liu, S. Kalnicki, M. Garg, A. Alfieri, and C. Guha
Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity
Cancer Res., August 15, 2007; 67(16): 7798 - 7806.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Udagawa, C. Kudo-Saito, G. Hasegawa, K. Yano, A. Yamamoto, M. Yaguchi, M. Toda, I. Azuma, T. Iwai, and Y. Kawakami
Enhancement of Immunologic Tumor Regression by Intratumoral Administration of Dendritic Cells in Combination with Cryoablative Tumor Pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation
Clin. Cancer Res., December 15, 2006; 12(24): 7465 - 7475.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Hu, X. Yuan, M. L. Belladonna, J. M. Ong, S. Wachsmann-Hogiu, D. L. Farkas, K. L. Black, and J. S. Yu
Induction of Potent Antitumor Immunity by Intratumoral Injection of Interleukin 23-Transduced Dendritic Cells.
Cancer Res., September 1, 2006; 66(17): 8887 - 8896.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. H. Kim, H. Jin, H. W. Kim, M.-H. Cho, and C. S. Cho
Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells.
Mol. Cancer Ther., July 1, 2006; 5(7): 1723 - 1732.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Melero, A. Arina, O. Murillo, J. Dubrot, C. Alfaro, J. L. Perez-Gracia, M. Bendandi, and S. Hervas-Stubbs
Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena
Clin. Cancer Res., April 15, 2006; 12(8): 2385 - 2389.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. L. Triozzi, K. O. Allen, R. R. Carlisle, M. Craig, A. F. LoBuglio, and R. M. Conry
Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma
Clin. Cancer Res., June 1, 2005; 11(11): 4168 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Mazzolini, C. Alfaro, B. Sangro, E. Feijoo, J. Ruiz, A. Benito, I. Tirapu, A. Arina, J. Sola, M. Herraiz, et al.
Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas
J. Clin. Oncol., February 10, 2005; 23(5): 999 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Mailliard, A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski
{alpha}-Type-1 Polarized Dendritic Cells: A Novel Immunization Tool with Optimized CTL-inducing Activity
Cancer Res., September 1, 2004; 64(17): 5934 - 5937.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Murakami, N. Tokunaga, T. Waku, S. Gomi, S. Kagawa, N. Tanaka, and T. Fujiwara
Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene
Clin. Cancer Res., June 1, 2004; 10(11): 3871 - 3880.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
M. Okamoto, G. Oh-e, T. Oshikawa, S. Furuichi, T. Tano, S. U. Ahmed, S. Akashi, K. Miyake, O. Takeuchi, S. Akira, et al.
Toll-Like Receptor 4 Mediates the Antitumor Host Response Induced by a 55-Kilodalton Protein Isolated from Aeginetia indica L., a Parasitic Plant
Clin. Vaccine Immunol., May 1, 2004; 11(3): 483 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al.
Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity
Clin. Cancer Res., April 15, 2004; 10(8): 2891 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Hillinger, S.-C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma
EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-{gamma}-Dependent Antitumor Responses in a Lung Cancer Model
J. Immunol., December 15, 2003; 171(12): 6457 - 6465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. Mcginn, and A. E. Chang
Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration
Cancer Res., December 1, 2003; 63(23): 8466 - 8475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos
Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound
Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Tatsumi, J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus
Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity
Cancer Res., October 1, 2003; 63(19): 6378 - 6386.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. Nishioka, H. Wen, K. Mitani, P. D. Robbins, M. T. Lotze, S. Sone, and H. Tahara
Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide
J. Leukoc. Biol., May 1, 2003; 73(5): 621 - 629.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Bello-Fernandez, J. Stasakova, A. Renner, N. Carballido-Perrig, M. Koening, M. Waclavicek, O. Madjic, L. Oehler, O. Haas, J. M. Carballido, et al.
Retrovirus-mediated IL-7 expression in leukemic dendritic cells generated from primary acute myelogenous leukemias enhances their functional properties
Blood, March 15, 2003; 101(6): 2184 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Mashino, N. Sadanaga, F. Tanaka, M. Ohta, H. Yamaguchi, and M. Mori
Effective Strategy of Dendritic Cell-based Immunotherapy for Advanced Tumor-bearing Hosts: the Critical Role of Th1-dominant Immunity
Mol. Cancer Ther., August 1, 2002; 1(10): 785 - 794.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yang, T. F. Witham, L. Villa, M. Erff, J. Attanucci, S. Watkins, D. Kondziolka, H. Okada, I. F. Pollack, and W. H. Chambers
Glioma-associated Hyaluronan Induces Apoptosis in Dendritic Cells via Inducible Nitric Oxide Synthase: Implications for the Use of Dendritic Cells for Therapy of Gliomas
Cancer Res., May 1, 2002; 62(9): 2583 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Ali, J. Lynam, C. S. McLean, C. Entwisle, P. Loudon, J. M. Rojas, S. E. B. McArdle, G. Li, S. Mian, and R. C. Rees
Tumor Regression Induced by Intratumor Therapy with a Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) Vector, DISC/HSV/Murine Granulocyte-Macrophage Colony-Stimulating Factor, Correlates with Antigen-Specific Adaptive Immunity
J. Immunol., April 1, 2002; 168(7): 3512 - 3519.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Kirk, D. Hartigan-O'Connor, and J. J. Mule
The Dynamics of the T-Cell Antitumor Response: Chemokine-secreting Dendritic Cells Can Prime Tumor-reactive T Cells Extranodally
Cancer Res., December 1, 2001; 61(24): 8794 - 8802.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tong, W. Song, and R. G. Crystal
Combined Intratumoral Injection of Bone Marrow-derived Dendritic Cells and Systemic Chemotherapy to Treat Pre-existing Murine Tumors
Cancer Res., October 1, 2001; 61(20): 7530 - 7535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Kirk, D. Hartigan-O’Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mulé
T Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine: Augmentation of Dendritic Cell-based Immunotherapy
Cancer Res., March 1, 2001; 61(5): 2062 - 2070.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
F. Tanaka, W. Hashimoto, H. Okamura, P. D. Robbins, M. T. Lotze, and H. Tahara
Rapid Generation of Potent and Tumor-specific Cytotoxic T Lymphocytes by Interleukin 18 Using Dendritic Cells and Natural Killer Cells
Cancer Res., September 1, 2000; 60(17): 4838 - 4844.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
G. Pirtskhalaishvili, G. V. Shurin, A. Gambotto, C. Esche, M. Wahl, Z. R. Yurkovetsky, P. D. Robbins, and M. R. Shurin
Transduction of Dendritic Cells with Bcl-xL Increases Their Resistance to Prostate Cancer-Induced Apoptosis and Antitumor Effect in Mice
J. Immunol., August 15, 2000; 165(4): 1956 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Hirao, N. Onai, K. Hiroishi, S. C. Watkins, K. Matsushima, P. D. Robbins, M. T. Lotze, and H. Tahara
CC Chemokine Receptor-7 on Dendritic Cells Is Induced after Interaction with Apoptotic Tumor Cells: Critical Role in Migration from the Tumor Site to Draining Lymph Nodes
Cancer Res., April 1, 2000; 60(8): 2209 - 2217.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.